# Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

> **NCT05443971** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 4 (actual)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Stage III Lung Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Durvalumab
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT05443971
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-08
- **Primary completion:** 2025-06-28
- **Final completion:** 2025-12-17
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443971, "Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05443971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*